Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy

AKT in cancer: new molecular insights and advances in drug development

(2016) Prabhjot S. Mundi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design

(2016) Safiulla Basha Syed et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Silibilin-Induces Apoptosis in Breast Cancer Cells by Modulating p53, p21, Bak and Bcl-xl Pathways

(2015) Mohammad Bagher Pirouzpanah et al.   Asian Pacific Journal of Cancer Prevention

STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma

(2015) C. Wu et al.   BLOOD

Wnt/ -Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells

(2015) G.-B. Jang et al.   CANCER RESEARCH

Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy

(2015) Joaquim Bosch-Barrera et al.   CANCER TREATMENT REVIEWS

Roles of the Bcl-2/Bax Ratio, Caspase-8 and 9 in Resistance of Breast Cancer Cells to Paclitaxel

(2014) Simin Sharifi et al.   Asian Pacific Journal of Cancer Prevention

The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy

(2014) Fiona Tan et al.   CURRENT DRUG TARGETS

Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells

(2014) Won Ho Kil et al.   Annals of Surgical Treatment and Research

Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer

(2013) Harold Ting et al.   AAPS Journal

Gene methylation and silencing ofSOCS3in mantle cell lymphoma

(2013) Ommoleila Molavi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial–mesenchymal transition and stemness

(2013) Kaijie Wu et al.   CELLULAR SIGNALLING

Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy

(2013) Arash Falamarzian et al.   JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A

Silibinin – A Promising New Treatment for Cancer

(2012) Catherine Wing Ying Cheung et al.   Anti-Cancer Agents in Medicinal Chemistry

Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity

(2012) Fang Wu et al.   CELLULAR SIGNALLING

Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis

(2012) HENRIETTE KAUNTZ et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

(2012) XIAOCHUN WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells

(2011) Y. Zhang et al.   CELL BIOCHEMISTRY AND FUNCTION

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

(2011) Linda S. Steelman et al.   CELL CYCLE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Multiple Drug Resistance Mechanisms in Cancer

(2010) Bruce C. Baguley   MOLECULAR BIOTECHNOLOGY

A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)

(2009) Elena J. Ladas et al.   CANCER

STAT3 as a target for inducing apoptosis in solid and hematological tumors

(2008) Khandaker Al Zaid Siddiquee et al.   CELL RESEARCH

Silibinin Inhibits Established Prostate Tumor Growth, Progression, Invasion, and Metastasis and Suppresses Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Transgenic Adenocarcinoma of the Mouse Prostate Model Mice

(2008) R. P. Singh et al.   CLINICAL CANCER RESEARCH